分子製藥市場 - 全球產業規模、佔有率、趨勢、機會和預測，按作物來源、技術、應用、最終用戶、地區和競爭細分，2019-2029F

2023 年，全球分子製藥市場估值為15.8 億美元，預計在預測期內將出現令人印象深刻的成長，到2029 年複合年成長率為7.74%。令人興奮的前沿領域涉及利用基因改造植物或動物生產藥物的生物技術。這種創新方法提供了一種潛在的更具成本效益和可擴展的藥物生產方法，因為它利用生物體內的自然生物過程來產生複雜的藥用化合物。引入編碼生產藥物的特定基因。這些經過改造的生物體就像活工廠一樣，能夠生產大量這些有價值的物質。分子製藥的主要優點之一是它有可能克服傳統藥物製造方法的限制。透過利用生物體，這種方法可以利用生物系統固有的效率和可擴展性。它可以在生產地點方面提供更大的靈活性，因為藥品可以在田間種植或包含在專門的設施中。分子製藥可望生產透過傳統化學方法難以合成或成本高昂的複雜藥物。透過利用活體生物體複雜的生化途徑，研究人員可以獲得多種具有治療潛力的天然化合物。的潛力、酵素和荷爾蒙。基因工程技術的持續研究和進步不斷擴大這種創新方法的可能性，為新療法的開發鋪平了道路。

市場概況
預測期	2025-2029
2023 年市場規模	15.8億美元
2029 年市場規模	19.1億美元
2024-2029 年複合年成長率	7.74%
成長最快的細分市場	生技與製藥公司
最大的市場	北美洲

主要市場促進因素

加強工業和非工業團體之間的夥伴關係

相對於傳統蛋白質生產方法的優勢

增加生物農業技術的研究

對具有成本效益、可擴展且快速生產疫苗和治療性蛋白質的方法的需求不斷成長

主要市場挑戰

開發和擴大規模的成本高昂

污染風險

主要市場趨勢

對生物製品的需求不斷成長

疾病盛行率上升

細分市場洞察

技術洞察

最終使用者見解

區域洞察

目錄

第 1 章：產品概述

第 2 章：研究方法

第 3 章：執行摘要

第 4 章：客戶之聲

第 5 章：全球分子醫藥市場展望

• 市場規模及預測
  • 按價值
• 市佔率及預測
  • 依作物來源（玉米、大麥、菸草、紅花、稻米、苜蓿）
  • 依技術（基因槍、農桿菌滲透、電穿孔、農桿菌介導的基因轉殖、其他）
  • 依應用（重組抗體、荷爾蒙、疫苗、工業酵素、蛋白質及蛋白質基材料、技術試劑、營養作物來源、其他）
  • 按最終用戶（生物技術和製藥公司、合約製造組織、其他）
  • 按地區
  • 按公司分類 (2023)
• 市場地圖

第 6 章：北美分子醫藥市場展望

• 市場規模及預測
  • 按價值
• 市佔率及預測
  • 按作物來源
  • 依技術
  • 按申請
  • 按最終用戶
  • 按國家/地區
• 北美：國家分析
  • 美國
  • 加拿大
  • 墨西哥

第 7 章：歐洲分子醫藥市場展望

• 市場規模及預測
  • 按價值
• 市佔率及預測
  • 按作物來源
  • 依技術
  • 按申請
  • 按最終用戶
  • 按國家/地區
• 歐洲：國家分析
  • 德國
  • 英國
  • 義大利
  • 法國
  • 西班牙

第 8 章：亞太分子醫藥市場展望

• 市場規模及預測
  • 按價值
• 市佔率及預測
  • 按作物來源
  • 依技術
  • 按申請
  • 按最終用戶
  • 按國家/地區
• 亞太地區：國家分析
  • 中國
  • 印度
  • 日本
  • 韓國
  • 澳洲

第 9 章：南美洲分子醫藥市場展望

• 市場規模及預測
  • 按價值
• 市佔率及預測
  • 按作物來源
  • 依技術
  • 按申請
  • 按最終用戶
  • 按國家/地區
• 南美洲：國家分析
  • 巴西
  • 阿根廷
  • 哥倫比亞

第 10 章：中東和非洲分子醫藥市場展望

• 市場規模及預測
  • 按價值
• 市佔率及預測
  • 按作物來源
  • 依技術
  • 按申請
  • 按最終用戶
  • 按國家/地區
• MEA：國家分析
  • 南非
  • 沙烏地阿拉伯
  • 阿拉伯聯合大公國

第 11 章：市場動態

• 促進要素
• 挑戰

第 12 章：市場趨勢與發展

• 近期發展
• 併購
• 產品發布

第 13 章：全球分子製藥市場：SWOT 分析

第 14 章：波特的五力分析

• 產業競爭
• 新進入者的潛力
• 供應商的力量
• 客戶的力量
• 替代產品的威脅

第15章：競爭格局

• Agrenvec SL
• Diamante SRL
• Leaf Systems International Limited
• Medicago Inc
• Meristem Therapeutics SA
• Moolec Science SA
• ORF Genetics
• Pfizer, Inc.
• ProdiGene Inc
• Protalix Biotherapeutics, Inc.

第 16 章：策略建議

第17章調查會社について,免責事項

Global Molecular Pharming Market was valued at USD 1.58 Billion in 2023 and is anticipated to project impressive growth in the forecast period with a CAGR of 7.74% through 2029. Molecular pharming, also known as molecular farming, is an exciting and cutting-edge field of biotechnology that involves leveraging genetically modified plants or animals to produce pharmaceuticals. This innovative approach offers a potentially more cost-effective and scalable method of drug production, as it harnesses the natural biological processes within organisms to generate complex medicinal compounds.By genetically engineering plants or animals, scientists can introduce specific genes that encode for the production of therapeutic proteins, biopharmaceuticals, and even vaccines. These modified organisms then serve as living factories, capable of producing large quantities of these valuable substances. One of the key advantages of molecular pharming is its potential to overcome the limitations of traditional drug manufacturing methods. By utilizing living organisms, this approach can tap into the inherent efficiency and scalability of biological systems. It can offer greater flexibility in terms of production location, as pharmaceuticals can be grown in fields or contained within specialized facilities. Molecular pharming holds the promise of producing complex pharmaceuticals that are difficult or costly to synthesize through traditional chemical means. By leveraging the intricate biochemical pathways of living organisms, researchers can access a wide array of naturally occurring compounds that have therapeutic potential.While molecular pharming is still a relatively young field, it has already demonstrated its potential in the production of various pharmaceuticals, including antibodies, enzymes, and hormones. Ongoing research and advancements in genetic engineering techniques continue to expand the possibilities of this innovative approach, paving the way for the development of novel treatments and therapies.

Market Overview
Forecast Period	2025-2029
Market Size 2023	USD 1.58 Billion
Market Size 2029	USD 1.91 Billion
CAGR 2024-2029	7.74%
Fastest Growing Segment	Biotechnology & Pharmaceutical Companies
Largest Market	North America

Key Market Drivers

Increasing Partnerships Between Industry and Non-Industry Groups

The field of molecular pharming is on the cusp of a transformative revolution, due in large part to the increasing partnerships between industry and non-industry groups. This collaborative approach is poised to significantly boost the demand for molecular pharming, revolutionizing the production of biopharmaceuticals and therapeutics. Traditionally, the pharmaceutical industry operated within its own boundaries, but the realization that the challenges of today's complex healthcare landscape require a multidisciplinary approach has led to these cross-sector partnerships.

Collaborative efforts enable the sharing of resources, reducing costs and the risk of duplication. This allows for more significant investments in research, technology development, and infrastructure for molecular pharming. Partnerships facilitate the exchange of diverse perspectives and ideas. The inclusion of non-industry groups can lead to innovative approaches and breakthroughs in the field, potentially unlocking new applications and markets for molecular pharming. By working together, industry and non-industry groups can accelerate the translation of research findings into practical applications. This means faster development and commercialization of biopharmaceuticals, which is crucial in addressing urgent healthcare needs. The increasing partnerships between industry and non-industry groups are expected to play a pivotal role in the growth of molecular pharming. This collaborative synergy not only fosters innovation and efficiency but also enables the industry to meet the rising demand for biopharmaceuticals, ultimately benefiting patients worldwide by improving access to cutting-edge treatments and therapies.

Advantages Over Traditional Methods of Protein Production

Molecular pharming, a revolutionary approach to protein production, offers numerous advantages compared to traditional methods. One of the key benefits is the ease of growing plants, which require minimal processing, leading to reduced production costs. Plant-based production systems are widely recognized for their safety, as plants are less prone to viral transmission or other contaminants, ensuring the integrity of the final product. The scalability of molecular pharming allows for large-scale production to meet the growing demands of protein-based therapeutics and other applications.

This emerging field holds tremendous potential for customization and optimization. Genetic engineering techniques can be employed to enhance protein expression and modify specific traits in plants, tailoring them to meet specific needs. This level of customization opens up new possibilities for the development of novel therapeutics and the production of proteins with enhanced functionalities.

With these unique characteristics, molecular pharming presents a promising avenue for the future of protein production. It not only addresses the challenges of cost, safety, scalability, and customization but also provides the opportunity for continuous innovation in the field. As research and technology in molecular pharming continue to advance, we can expect even greater breakthroughs and applications in the production of proteins for various industries, including pharmaceuticals, agriculture, and biotechnology.

Increased Research in Bio-Farming Techniques

The growing focus on research in biopharming techniques is poised to drive increased demand for molecular pharming in the pharmaceutical and biotechnology sectors. Molecular pharming, or biopharming, involves the use of genetically engineered plants or animals to produce therapeutic proteins, vaccines, and other biopharmaceuticals. Ongoing research is leading to the development of more efficient and precise techniques for molecular pharming. This includes advancements in gene editing technologies like CRISPR/Cas9, which enable scientists to precisely modify host organisms for higher yields and improved product quality. These innovations can reduce production costs and make molecular pharming a more attractive option for biopharmaceutical companies. Researchers are exploring a wider range of host organisms for molecular pharming, including algae, fungi, and insects. These efforts are expanding the possibilities for producing a broader array of biopharmaceuticals, including those that were previously challenging or expensive to manufacture.

As concerns about environmental sustainability grow, research in biopharming is driving the development of more sustainable production methods. Plants, for example, offer a more environmentally friendly alternative to traditional mammalian cell cultures. This aligns with the broader trend in the pharmaceutical industry towards greener and more sustainable practices. The expanding body of research in biopharming techniques is fundamentally reshaping the landscape of pharmaceutical production. As these techniques become more efficient, versatile, and sustainable, they are expected to play a pivotal role in meeting the growing demand for biopharmaceuticals, ultimately benefiting patients by providing more affordable and accessible treatments.

Growing Demand for Cost-Effective, Scalable, And Fast Methods Of Producing Vaccines And Therapeutic Proteins

The growing demand for cost-effective, scalable, and fast methods of producing vaccines and therapeutic proteins is expected to fuel the rising demand for molecular pharming. Molecular pharming, also known as biopharming, involves the use of genetically modified plants or animals to produce pharmaceuticals, including vaccines and therapeutic proteins. Traditional biopharmaceutical production methods, such as mammalian cell culture, can be costly due to the need for specialized facilities and equipment. Molecular pharming, on the other hand, often requires fewer resources and lower operational costs. This cost-effectiveness is especially valuable in providing affordable vaccines and therapies to a wider population. Molecular pharming allows for the customization of host organisms to produce specific vaccines and therapeutic proteins efficiently. This flexibility enables the tailoring of production to address diverse medical needs, including emerging diseases and rare disorders. The increasing demand for vaccines to prevent infectious diseases, including those caused by emerging pathogens, highlights the importance of rapid and efficient vaccine production methods. Molecular pharming's speed and adaptability make it well-suited for this purpose.

Key Market Challenges

High Costs of Development and Scale-Up

The high costs of development and scale-up pose significant hurdles to the growth of molecular pharming and its ability to meet the rising demand for biopharmaceuticals. Molecular pharming, a biotechnology approach that utilizes genetically modified plants or animals to produce therapeutic proteins and pharmaceuticals, offers numerous advantages, including scalability, versatility, and potentially reduced production expenses. However, the initial stages of development and the subsequent scaling of production can be prohibitively expensive.

In the early phases of molecular pharming, substantial investments are required for research and development. This includes the genetic engineering of host organisms, optimization of production processes, and ensuring the safety and efficacy of the resulting biopharmaceuticals. These endeavors demand specialized expertise, cutting-edge laboratory facilities, and extensive testing, all of which incur substantial costs. Scaling up production to meet the demand for biopharmaceuticals on a commercial level is a complex and costly endeavor. The construction of large-scale bioreactors, greenhouses, or animal facilities, as well as the implementation of stringent quality control measures, significantly add to the expenses. Achieving consistent and reliable yields while maintaining product quality is paramount but can be financially daunting.

The high costs associated with molecular pharming can deter both private sector investment and academic research initiatives. This financial barrier may limit the number of organizations and researchers willing and able to participate in advancing the technology. As a result, the pace of innovation and the availability of molecular pharming-derived biopharmaceuticals may be constrained, hindering its ability to fully address the growing demand for these critical medical treatments.

Risks of Contamination

The risks of contamination represent a substantial obstacle to the growth of molecular pharming and its potential to meet the escalating demand for biopharmaceuticals. Molecular pharming involves the use of genetically modified plants or animals to produce therapeutic proteins and pharmaceuticals, and maintaining a sterile and controlled production environment is paramount. Contamination in the form of pathogens, unintended genetic changes, or cross-contamination from nearby crops or animals can have severe consequences on product safety and efficacy, leading to significant challenges for the industry. One of the primary concerns is the introduction of pathogens or harmful substances into the production process. Even a single instance of contamination can compromise the entire batch of biopharmaceuticals, rendering them unsafe for human use. This risk not only poses a threat to patient safety but also triggers costly recalls and regulatory setbacks, damaging the reputation and financial stability of the organizations involved.

Another risk is the potential for unintended genetic changes or mutations in the host organisms. These changes can affect the stability and consistency of biopharmaceutical production, leading to variations in product quality and efficacy. Ensuring genetic stability and maintaining precise control over the host organisms is an ongoing challenge in molecular pharming. Cross-contamination is yet another concern, particularly in open-field settings. Pollen or seeds from genetically modified crops can unintentionally spread to nearby non-GMO crops, posing ecological and regulatory risks. Containment measures must be rigorously enforced to prevent unintended gene flow and maintain the integrity of both GM and non-GM crops. These contamination risks not only impose stringent requirements for quality control and monitoring but also add substantial operational costs. The need for dedicated secure facilities, regular testing, and rigorous sanitation protocols drives up the expenses associated with molecular pharming.

Key Market Trends

Rising Demand for Biologics

The global pharmaceutical industry is witnessing a significant shift towards biologics, a class of drugs derived from living organisms such as bacteria, yeast, or mammalian cells. This surge in demand for biologics is primarily driven by their ability to target complex diseases, deliver more personalized treatments, and reduce side effects compared to traditional small molecule drugs. As the demand for biologics continues to rise, so does the need for efficient and scalable production methods, leading to a growing interest in molecular pharming.

Molecular pharming aligns with the growing emphasis on sustainability and environmentally friendly production methods. Plants, for instance, can be grown in controlled environments using fewer resources and with a smaller carbon footprint compared to traditional biologics production in mammalian cell cultures.

The rising demand for biologics is poised to drive the adoption of molecular pharming technologies. This innovative approach not only addresses the increasing need for cost-effective and scalable biologics production but also supports sustainability goals within the pharmaceutical industry. As research and development in molecular pharming advance, we can anticipate a more efficient and accessible supply of biologic drugs for patients worldwide.

Rising Prevalence of Disease Indications

The global healthcare landscape is confronting a relentless increase in the prevalence of various diseases, ranging from chronic conditions like diabetes and cancer to emerging infectious diseases. This growing health burden necessitates the development and production of innovative therapeutic solutions, particularly biologics. The rising prevalence of disease indications is expected to drive an increased demand for molecular pharming as a critical component of the pharmaceutical industry's response to these healthcare challenges. Molecular pharming provides a scalable and cost-effective production platform. It allows for the rapid and large-scale production of biologics in plants or animals, enabling the pharmaceutical industry to meet the heightened demand for these therapies efficiently. This scalability is particularly vital in addressing diseases with widespread prevalence, where large quantities of biologics are required.Molecular pharming supports the development of vaccines and therapeutics for emerging diseases. When new infectious diseases arise, such as novel viruses or strains of pathogens, molecular pharming can rapidly adapt to produce vaccines and treatments, helping to control outbreaks more effectively. The rising prevalence of disease indications is set to intensify the demand for molecular pharming as an indispensable tool in the pharmaceutical industry's efforts to develop, produce, and supply biologics. Its scalability, flexibility, and adaptability make it a crucial technology in combating both common and emerging diseases, ultimately improving global healthcare outcomes.

Segmental Insights

Technology Insights

Based on the technology, The Agrobacterium-Mediated Gene Transfer (AMGT) technology is poised to dominate the global molecular pharming market. This groundbreaking and cutting-edge technique, renowned for its exceptional efficiency and remarkable adaptability to a wide range of host plants, harnesses the natural genetic engineering capabilities of Agrobacterium tumefaciens to facilitate the precise delivery of genetic information into plant cells. Through this innovative process, AMGT enables the production of recombinant proteins with unparalleled success, solidifying its prominence in the field of molecular pharming. This remarkable technology paves the way for groundbreaking advancements in the realm of biotechnology, propelling us into a new era of sustainable and high-yield protein production. With its extraordinary potential and unrivaled capabilities, AMGT is revolutionizing the landscape of molecular pharming and opening doors to limitless possibilities in the field of biopharmaceutical research and development.

End User Insights

Based on the end user segment, Biotechnology & Pharmaceutical Companies that hold a significant dominance. This can be attributed to their robust financial capabilities, providing them with the opportunity to make substantial investments in research and development (R&D), thereby accelerating progress in the field of molecular pharming. Through their dedication to scientific breakthroughs, these companies continuously explore new frontiers, uncovering innovative solutions that revolutionize the industry.

The success of Biotechnology & Pharmaceutical Companies can be attributed to their extensive and well-established distribution networks. These networks enable them to penetrate diverse markets and effectively reach a larger customer base. By leveraging their strong financial prowess, these companies are able to invest in strategic partnerships and collaborations, fostering growth and unlocking new opportunities in the molecular pharming industry. With their relentless pursuit of scientific advancements, financial capabilities, and expansive reach, Biotechnology & Pharmaceutical Companies continue to shape and drive the growth of the global molecular pharming industry, setting the stage for a promising future.

Regional Insights

The North American region is anticipated to continue dominating the global molecular pharming market. This is primarily attributed to its advanced bio-pharmaceutical industry, characterized by cutting-edge research and development initiatives. The region hosts key players who contribute significantly to the growth of this market. The increasing prevalence of chronic diseases in North America, coupled with the rising demand for cost-effective therapies, further fuels the expansion of the molecular pharming market in the region.

The region's robust healthcare infrastructure, including state-of-the-art facilities and a well-established regulatory framework, provides a conducive environment for the development and commercialization of molecular pharming products. The presence of top-tier academic institutions and research centers also fosters collaboration and innovation in the field, attracting talent and investment from around the globe.

In addition, the North American market benefits from a strong network of distribution channels and well-established supply chain management, facilitating efficient and timely delivery of molecular pharming products to healthcare providers and patients. The region's high healthcare expenditure and reimbursement policies further contribute to market growth, ensuring accessibility and affordability of these advanced therapies. With these factors at play, North America is poised to maintain its leadership position in this dynamic industry, driving innovation and shaping the future of molecular pharming on a global scale.

Key Market Players

Agrenvec S.L

Diamante SRL

Leaf Systems International Limited

Medicago Inc

Meristem Therapeutics S.A.

Moolec Science SA

ORF Genetics

Pfizer, Inc.

ProdiGene Inc

Protalix Biotherapeutics, Inc.

Report Scope:

In this report, the Global Molecular Pharming Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Molecular Pharming Market, By Crop Source:

Maize Barley Tobacco Safflower Rice Alfalfa

Molecular Pharming Market, By Technology:

Gene Gun Agroinfiltration Electroporation Agrobacterium-Mediated Gene Transfer Others

Molecular Pharming Market, By Application:

Recombinant Antibodies Hormones Vaccines Industrial Enzymes Proteins & Protein-Based Materials Technical Reagents Nutritional Crop Sources Others

Molecular Pharming Market, By End User:

Biotechnology & Pharmaceutical Companies Contract Manufacturing Organizations Others

Molecular Pharming Market, By Region:

North America

United States

Canada

Mexico

Europe

France

United Kingdom

Italy

Germany

Spain

Asia-Pacific

China

India

Japan

Australia

South Korea

South America

Brazil

Argentina

Colombia

Middle East & Africa

South Africa

Saudi Arabia

UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Molecular Pharming Market.

Available Customizations:

Global Molecular Pharming market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validations
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Molecular Pharming Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Crop Source (Maize, Barley, Tobacco, Safflower, Rice, Alfalfa)
  • 5.2.2. By Technology (Gene Gun, Agroinfiltration, Electroporation, Agrobacterium-Mediated Gene Transfer, Others)
  • 5.2.3. By Application (Recombinant Antibodies, Hormones, Vaccines, Industrial Enzymes, Proteins & Protein-Based Materials, Technical Reagents, Nutritional Crop Sources, Others)
  • 5.2.4. By End User (Biotechnology & Pharmaceutical Companies, Contract Manufacturing Organizations, Others)
  • 5.2.5. By Region
  • 5.2.6. By Company (2023)
• 5.3. Market Map

6. North America Molecular Pharming Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Crop Source
  • 6.2.2. By Technology
  • 6.2.3. By Application
  • 6.2.4. By End User
  • 6.2.5. By Country
• 6.3. North America: Country Analysis
  • 6.3.1. United States Molecular Pharming Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Crop Source
      • 6.3.1.2.2. By Technology
      • 6.3.1.2.3. By Application
      • 6.3.1.2.4. By End User
  • 6.3.2. Canada Molecular Pharming Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Crop Source
      • 6.3.2.2.2. By Technology
      • 6.3.2.2.3. By Application
      • 6.3.2.2.4. By End User
  • 6.3.3. Mexico Molecular Pharming Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Crop Source
      • 6.3.3.2.2. By Technology
      • 6.3.3.2.3. By Application
      • 6.3.3.2.4. By End User

7. Europe Molecular Pharming Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Crop Source
  • 7.2.2. By Technology
  • 7.2.3. By Application
  • 7.2.4. By End User
  • 7.2.5. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. Germany Molecular Pharming Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Crop Source
      • 7.3.1.2.2. By Technology
      • 7.3.1.2.3. By Application
      • 7.3.1.2.4. By End User
  • 7.3.2. United Kingdom Molecular Pharming Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Crop Source
      • 7.3.2.2.2. By Technology
      • 7.3.2.2.3. By Application
      • 7.3.2.2.4. By End User
  • 7.3.3. Italy Molecular Pharming Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Crop Source
      • 7.3.3.2.2. By Technology
      • 7.3.3.2.3. By Application
      • 7.3.3.2.4. By End User
  • 7.3.4. France Molecular Pharming Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Crop Source
      • 7.3.4.2.2. By Technology
      • 7.3.4.2.3. By Application
      • 7.3.4.2.4. By End User
  • 7.3.5. Spain Molecular Pharming Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Crop Source
      • 7.3.5.2.2. By Technology
      • 7.3.5.2.3. By Application
      • 7.3.5.2.4. By End User

8. Asia-Pacific Molecular Pharming Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Crop Source
  • 8.2.2. By Technology
  • 8.2.3. By Application
  • 8.2.4. By End User
  • 8.2.5. By Country
• 8.3. Asia-Pacific: Country Analysis
  • 8.3.1. China Molecular Pharming Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Crop Source
      • 8.3.1.2.2. By Technology
      • 8.3.1.2.3. By Application
      • 8.3.1.2.4. By End User
  • 8.3.2. India Molecular Pharming Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Crop Source
      • 8.3.2.2.2. By Technology
      • 8.3.2.2.3. By Application
      • 8.3.2.2.4. By End User
  • 8.3.3. Japan Molecular Pharming Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Crop Source
      • 8.3.3.2.2. By Technology
      • 8.3.3.2.3. By Application
      • 8.3.3.2.4. By End User
  • 8.3.4. South Korea Molecular Pharming Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Crop Source
      • 8.3.4.2.2. By Technology
      • 8.3.4.2.3. By Application
      • 8.3.4.2.4. By End User
  • 8.3.5. Australia Molecular Pharming Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Crop Source
      • 8.3.5.2.2. By Technology
      • 8.3.5.2.3. By Application
      • 8.3.5.2.4. By End User

9. South America Molecular Pharming Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Crop Source
  • 9.2.2. By Technology
  • 9.2.3. By Application
  • 9.2.4. By End User
  • 9.2.5. By Country
• 9.3. South America: Country Analysis
  • 9.3.1. Brazil Molecular Pharming Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Crop Source
      • 9.3.1.2.2. By Technology
      • 9.3.1.2.3. By Application
      • 9.3.1.2.4. By End User
  • 9.3.2. Argentina Molecular Pharming Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Crop Source
      • 9.3.2.2.2. By Technology
      • 9.3.2.2.3. By Application
      • 9.3.2.2.4. By End User
  • 9.3.3. Colombia Molecular Pharming Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Crop Source
      • 9.3.3.2.2. By Technology
      • 9.3.3.2.3. By Application
      • 9.3.3.2.4. By End User

10. Middle East and Africa Molecular Pharming Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Crop Source
  • 10.2.2. By Technology
  • 10.2.3. By Application
  • 10.2.4. By End User
  • 10.2.5. By Country
• 10.3. MEA: Country Analysis
  • 10.3.1. South Africa Molecular Pharming Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Crop Source
      • 10.3.1.2.2. By Technology
      • 10.3.1.2.3. By Application
      • 10.3.1.2.4. By End User
  • 10.3.2. Saudi Arabia Molecular Pharming Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Crop Source
      • 10.3.2.2.2. By Technology
      • 10.3.2.2.3. By Application
      • 10.3.2.2.4. By End User
  • 10.3.3. UAE Molecular Pharming Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Crop Source
      • 10.3.3.2.2. By Technology
      • 10.3.3.2.3. By Application
      • 10.3.3.2.4. By End User

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Recent Development
• 12.2. Mergers & Acquisitions
• 12.3. Product Launches

13. Global Molecular Pharming Market: SWOT Analysis

14. Porter's Five Forces Analysis

• 14.1. Competition in the Industry
• 14.2. Potential of New Entrants
• 14.3. Power of Suppliers
• 14.4. Power of Customers
• 14.5. Threat of Substitute Products

15. Competitive Landscape

• 15.1. Agrenvec S.L
  • 15.1.1. Business Overview
  • 15.1.2. Company Snapshot
  • 15.1.3. Products & Services
  • 15.1.4. Financials (As Reported)
  • 15.1.5. Recent Developments
  • 15.1.6. Key Personnel Details
  • 15.1.7. SWOT Analysis
• 15.2. Diamante SRL
• 15.3. Leaf Systems International Limited
• 15.4. Medicago Inc
• 15.5. Meristem Therapeutics S.A.
• 15.6. Moolec Science SA
• 15.7. ORF Genetics
• 15.8. Pfizer, Inc.
• 15.9. ProdiGene Inc
• 15.10. Protalix Biotherapeutics, Inc.

16. Strategic Recommendations

17. About Us & Disclaimer